The US government launched a trade investigation into Germany’s drug pricing system amid the country’s review of health-care spending. The probe is filed under Section 301 of the Trade Act of 1974, a move that could expand pressure on how medicines are priced and reimbursed across the EU’s largest market. The investigation underscores how US policy tools are increasingly being used to challenge foreign pharmaceutical pricing frameworks, potentially affecting market access planning for multinational biopharma companies. Regulators and industry stakeholders will now watch for further scope details, including potential remedy pathways and timelines tied to the Section 301 process.